Tag: Covid19 Essential
This Thanksgiving, with so many families unable or unwilling (often smartly), to get together during the holiday, such a historically lazy and obvious answer has been suddenly endowed with real meaning.
Yes, even after that Pfizer thing. And neither are any of those cruise or airplane stocks. While the week began as the long-awaited rotation out of stay-at-home tech and into the beaten-down travel sector, the rotation already came and went. It lasted a whole day, long enough to sell those cruise stocks on the pop—I did.
Health insurer UnitedHealth Group (NYSE: UNH) rose 10%, while Cigna Corp (NYSE: CI) andAnthem Inc (NYSE: ANTM) jumped by double digits. These three stocks are solid buys for broad-sector exposure. But there is no healthcare company more perfectly positioned to benefit for what will be a long, dark winter of germs than Teledoc (NYSE: TDOC).
On August 14, Pet Vivo Holdings, Inc. (OTCQB: PETV) filed its quarterly report for the period ending June 30, 2020. In it, it showed current liabilities of $2.14 million. Since then, the company settled over $600,000.00 in liabilities which is reflected in recent 8K “material event” filings, as well as in its next quarterly report.
Back in July, the stock was given a target price of between $1.74 and $2.32 per share by Marble Arch Research. You can download the full report here: - Among other results, the report states “At ~1x FY23 sales, the stock is substantially undervalued relative to its comps mostly trading in a comparable 3X-4X P/S multiple range.”
Recently trading at around .70 per share, PetVivo Holdings, Inc. (OTCQB: PETV) just announced something interesting on Tuesday which brought a $1.40 share price and what could be the beginning of a strong accumulation of their stock.
Neuronetics’ flagship product is the NeuroStar Advanced Therapy System. NeuroStar uses transcranial magnetic stimulation (TMS) to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.
The stock was in the green this week after releasing another denial of fraud allegations levied at the company courtesy of Wolfpack Research back in April. Citing in-person surveys of more than 1,500 people and Chinese credit reports of iQiyi’s VIEs and WFOEs, the short seller claimed that the Chinese entertainment platform overstated its user numbers and inflated its revenues in SEC filings by as much as 261.7% pre-IPO. Further, in 2019, Wolfpack estimated that iQiyi inflated revenue by 27% to 44%. Are they another Luckin Coffee? Maybe. But like Luckin, iQiyi can be both a liar and long-term winner. The SEC launched a probe into iQiyi and its parent company, Baidu (Nasdaq: BIDU).
The new PetVivo medical device facility, primarily dedicated to the manufacture of its veterinary medical device for the treatment of osteoarthritis (OA), KUSH™ will serve as the primary location for PetVivo medical device operations, which provides manufacturing capabilities to produce up to 500,000 syringes of Kush that could generate over $100 million in revenue annually.
Most of us know the story of Luckin Coffee. In a nutshell, the company was supposed to be the Starbucks of China, giving the American coffee giant a run for its money on the Mainland. The Beijing-based company launched in 2017 and quickly grew its stores and pick-up locations to rival Starbucks (Nasdaq: SBUX) in China. The stock exploded in popularity. And then, it just exploded.